Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Express Scripts
Medtronic
McKinsey
Moodys

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Gemini Labs Llc Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the competitive landscape for GEMINI LABS LLC, and what generic and branded alternatives to GEMINI LABS LLC drugs are available?

GEMINI LABS LLC has two approved drugs.



Summary for Gemini Labs Llc
US Patents:0
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Gemini Labs Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-002 Nov 5, 2001 DISCN Yes No   Start Trial   Start Trial
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-002 Dec 22, 1997 DISCN Yes No   Start Trial   Start Trial
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-001 Dec 22, 1997 DISCN Yes No   Start Trial   Start Trial
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-003 Dec 22, 1997 DISCN Yes No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Gemini Labs Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-002 Dec 22, 1997 5,216,167   Start Trial
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-002 Dec 22, 1997 4,873,080   Start Trial
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-002 Nov 5, 2001 6,090,799   Start Trial
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-002 Dec 22, 1997 6,143,769   Start Trial
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-001 Dec 22, 1997 6,677,358   Start Trial
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-001 Dec 22, 1997 5,216,167   Start Trial
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-001 Approved Prior to Jan 1, 1982 5,872,147   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for GEMINI LABS LLC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 2.5 mg and 10 mg ➤ Subscribe 2006-06-19
➤ Subscribe Tablets 0.5 mg, 1 mg and 2 mg ➤ Subscribe 2005-02-10
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
McKesson
Merck
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.